ICER Suggests Big Price Cut For Novartis’s New PNH Drug
Executive Summary
The pricing watchdog said 94% of Fabhalta’s price comes from offsetting the cost of AstraZeneca’s Ultomiris, while Novartis said ICER’s analysis has “substantial challenges.”